600252 Guangxi Wuzhou Zhongheng Group
- 2.48
- -0.03-1.20%
Guangxi Wuzhou Zhongheng Group News
Zhongheng Group (600252.SH): A total of 12.103 million shares have been repurchased
Gelonghui Group (600252.SH) announced on May 7, 2024, that as of April 30, 2024, the company had repurchased 12,103,000 shares of the company through centralized bidding transactions, accounting for 0.35% of the company's total share capital of 3,451,489,454 shares. The highest price of the repurchase transaction was 2.44 yuan/share, the lowest price was 2.20 yuan/share, and the total amount of capital paid was RMB 27,023,304.00 (excluding transaction fees such as stamp duty and transaction fees).
Why Investors Shouldn't Be Surprised By Guangxi Wuzhou Zhongheng Group Co.,Ltd's (SHSE:600252) Low P/S
With a price-to-sales (or "P/S") ratio of 2.6x Guangxi Wuzhou Zhongheng Group Co.,Ltd (SHSE:600252) may be sending bullish signals at the moment, given that almost half of all the Pharmaceuticals comp
Zhongheng Group (600252.SH): Net profit of 54.711,200 yuan in the first quarter
Gelonghui, April 29丨Zhonghui Group (600252.SH) released its report for the first quarter of 2024, achieving operating income of 806 million yuan, an increase of 20.34% over the previous year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss of RMB 26.0875 million, an increase of 1461.09% over the previous year; net profit attributable to shareholders of listed companies was 54.7112 million yuan, with basic earnings per share of 0.016 yuan.
Zhongheng Group (600252.SH): Initial repurchase of 0.21% of shares
Gelonghui Group (600252.SH) announced on April 16, 2024, that on April 16, 2024, the company repurchased 7,168,600 shares of the company's shares for the first time through centralized bidding transactions, accounting for 0.21% of the company's total share capital of 3,451,489,454 shares. The highest price of the repurchase transaction was 2.25 yuan/share, the lowest price was 2.20 yuan/share, and the total amount of capital paid was RMB 15,959,328.00 (excluding transaction fees such as stamp duty and transaction fees).
We Like The Quality Of Guangxi Wuzhou Zhongheng GroupLtd's (SHSE:600252) Earnings
Guangxi Wuzhou Zhongheng Group Co.,Ltd's (SHSE:600252) recent earnings report didn't offer any surprises, with the shares unchanged over the last week. Our analysis suggests that shareholders might b
Zhongheng Group (600252.SH): Shares have not been repurchased
Gelonghui, April 2, 丨 Zhongheng Group (600252.SH) announced that as of March 31, 2024, the company had not repurchased shares.
Zhongheng Group (600252.SH) announced its 2023 annual results, with net profit of 84.31 million yuan, an increase of 6.69% over the previous year. It plans to distribute 0.1 yuan to 10
Zhongheng Group (600252.SH) disclosed its 2023 annual report, and the company achieved revenue of 30 in 2023...
Express News | A Share Repurchase Overview: 35 Companies Disclose Repurchase Progress
Zhongheng Group (600252.SH) Holdings Sun Company obtained 2 medical device registration certificates
Zhongheng Group (600252.SH) announced that recently, the company holds Sun Company Hainan Laimei Medical Devices Co., Ltd. (...
Express News | Zhongheng Group: The holding subsidiary obtained a drug registration certificate
Lummy Pharma Gets Nod to Raise Dosage of Gastric Drug
China's National Medical Products Administration approved the application of Guangxi Wuzhou Zhongheng Group's (SHA:600252) unit, Chongqing Lummy Pharmaceutical (SHE:300006), to increase the dosage of
Shareholders 22% Loss in Guangxi Wuzhou Zhongheng GroupLtd (SHSE:600252) Partly Attributable to the Company's Decline in Earnings Over Past Five Years
For many, the main point of investing is to generate higher returns than the overall market. But the main game is to find enough winners to more than offset the losers At this point some shareholder
Express News | Zhongheng Group: The holding subsidiary received a notice of approval for injectable esomeprazole sodium supplementation
Express News | Frequent “deregive-out” repurchases of listed companies now boost confidence with real money
Express News | Real money rewards investors and listed companies take more measures to share “growth dividends”
Express News | Another large number of A-share companies set off a wave of buybacks
Express News | More than 20 listed companies announced plans to repurchase or increase their holdings today, and Shanxi Fenjiu plans to increase their holdings by up to 200 million yuan
Zhongheng Group (600252.SH) plans to spend 150 million yuan to 200 million yuan to repurchase shares at a repurchase price of no more than 3.34 yuan/share
Zhongheng Group (600252.SH) issued an announcement that the company plans to use its own funds to buy back the public through centralized bidding transactions...
Express News | Zhongheng Group: Nicodil received a notice of approval for the marketing application of chemical raw materials
Lacklustre Performance Is Driving Guangxi Wuzhou Zhongheng Group Co.,Ltd's (SHSE:600252) Low P/S
Guangxi Wuzhou Zhongheng Group Co.,Ltd's (SHSE:600252) price-to-sales (or "P/S") ratio of 2.7x might make it look like a buy right now compared to the Pharmaceuticals industry in China, where around h
Analysis
Price Target
No Data
